UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1125-1132

2011

Volltextzugriff (PDF)

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood, 2016-10, Vol.128 (14), p.1821-1828

2016

Volltextzugriff (PDF)

A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Clinical cancer research, 2007-03, Vol.13 (6), p.1762-1768

2007

Volltextzugriff (PDF)

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

American journal of hematology, 2009-10, Vol.84 (10), p.650-656

2009

Volltextzugriff (PDF)

NADPH Inhibits [2Fe-2S] Cluster Protein Transfer from Diabetes Drug Target MitoNEET to an Apo-acceptor Protein

The Journal of biological chemistry, 2012-04, Vol.287 (15), p.11649-11655

2012

Volltextzugriff (PDF)

Treatment for Myeloma Bone Disease

Clinical cancer research, 2006-10, Vol.12 (20), p.6279s-6284s

2006

Volltextzugriff (PDF)

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients

International journal of urology, 2014-12, Vol.21 (12), p.1239-1244

2014

Volltextzugriff (PDF)

Myeloma bone disease and treatment options

European journal of cancer (1990), 2006-07, Vol.42 (11), p.1554-1563

2006

Volltextzugriff (PDF)

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study

British journal of haematology, 2006-10, Vol.135 (2), p.174-183

2006

Volltextzugriff (PDF)

Dynamic Regulation of Cyclooxygenase-2 Promoter Activity by Isoforms of CCAAT/Enhancer-binding Proteins

The Journal of biological chemistry, 2002-03, Vol.277 (9), p.6923-6928

2002

Volltextzugriff (PDF)

Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy

Clinical lymphoma & myeloma, 2006-11, Vol.7 (3), p.192-198

2006

Volltextzugriff (PDF)

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Supportive care in cancer, 2014-03, Vol.22 (3), p.679-687

2014

Volltextzugriff (PDF)

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2571-2571

2021

Volltextzugriff (PDF)

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

Journal of bone and mineral research, 2010-03, Vol.25 (3), p.440-446

2010

Volltextzugriff (PDF)

Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status

British journal of haematology, 2006-06, Vol.133 (5), p.526-529

2006

Volltextzugriff (PDF)

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS8609-TPS8609

2015

Volltextzugriff (PDF)

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Blood, 2015-12, Vol.126 (23), p.507-507

2015

Volltextzugriff (PDF)

Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8533-8533

2014

Volltextzugriff (PDF)

Reduced Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Blocks Transfer of [2Fe-2S] Clusters from MitoNEET to an Apo-Acceptor Protein

Biophysical journal, 2012-01, Vol.102 (3), p.459a-459a

2012

Volltextzugriff (PDF)

Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study

Blood, 2011-11, Vol.118 (21), p.2483-2483

2011

Volltextzugriff (PDF)

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.84-84

2014

Volltextzugriff (PDF)

Myeloma bone disease and treatment options: 160 years of Multiple Myeloma: Progress and Challenges

European journal of cancer (1990), 2006, Vol.42 (11), p.1554-1563

2006

Volltextzugriff (PDF)

Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in K orean and T aiwanese patients

International journal of urology, 2014-12, Vol.21 (12), p.1239-1244

2014

Volltextzugriff (PDF)

Reply to S.M. Sorscher et al

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2736-2737

2011

Volltextzugriff (PDF)

Results From a Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trial Comparing Denosumab with Zoledronic Acid for the Management of Bone Metastases in Patients with Advanced Solid Tumors or Multiple Myeloma

Bone (New York, N.Y.), 2010, Vol.46, p.S44-S44

2010

Volltextzugriff (PDF)

1 – 25 von 375

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(331)

Publikationsform

Sprache

Englisch
(375)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

NADPH Inhibits [2Fe-2S] Cluster Protein Transfer from Diabetes Drug Target MitoNEET to an Apo-acceptor Protein

Treatment for Myeloma Bone Disease

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients

Myeloma bone disease and treatment options

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study

Dynamic Regulation of Cyclooxygenase-2 Promoter Activity by Isoforms of CCAAT/Enhancer-binding Proteins

Arsenic Compounds in the Treatment of Multiple Myeloma: A New Role for a Historical Remedy

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203)

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure

Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor)

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma

Reduced Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Blocks Transfer of [2Fe-2S] Clusters from MitoNEET to an Apo-Acceptor Protein

Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Myeloma bone disease and treatment options: 160 years of Multiple Myeloma: Progress and Challenges

Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in K orean and T aiwanese patients

Reply to S.M. Sorscher et al

Results From a Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trial Comparing Denosumab with Zoledronic Acid for the Management of Bone Metastases in Patients with Advanced Solid Tumors or Multiple Myeloma

Suchergebnisse filtern